Better Bet Than Danaher Stock: Pay Less To Get More From MEDP, IQV
MEDP, IQV are DHR’s peers in Life Sciences Tools & Services industry that have:
1) Lower valuation (P/EBIT) compared to DHR
2) But higher revenue and operating income growth
This disconnect between valuation and performance could mean that you are better off buying MEDP, IQV stocks vs. DHR
Key Metrics Compared
- Why Has MP Stock Halved?
- Amazon.com Stock on the Edge: 3 Threats You Need to Know
- Has HCA Healthcare Stock Quietly Become a Value Opportunity?
- If The World Is On Fire, Why Is Gold Getting Cheaper?
- Lockheed Martin Stock: Is The Iran War Already Priced In?
- Should You Pay Attention To Chevron Stock’s Momentum?
| Metric | DHR | MEDP | IQV |
|---|---|---|---|
| P/OpInc* | 29.3x | 28.8x | 14.1x |
| LTM OpInc Growth | -3.4% | 28.7% | 8.5% |
| 3Y Avg OpInc Growth | -8.7% | 28.8% | 13.3% |
| LTM Revenue Growth | 0.3% | 9.9% | 2.8% |
| 3Y Avg Revenue Growth | -2.4% | 21.4% | 3.4% |
OpInc = Operating Income, P/EBIT = Price To Operating Income Ratio
Danaher (DHR) designs and markets professional, medical, industrial products across Life Sciences, Diagnostics, and Environmental segments, offering advanced instruments and automation systems for research, diagnostics, and therapy.
This is just one approach to evaluate investments. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Is The Mismatch In Stock Price Temporary
One way to check if Danaher stock is expensive now versus the other tickers would be to see how these metrics compared across companies exactly a year ago. Specifically, if there has been a marked reversal in the trend for Danaher in the last 12 months, then there is a chance that the current mismatch is likely to reverse. On the other hand, a persistent underperformance in revenue and operating income growth for Danaher would reinforce the conclusion that the stock is expensive compared to its peers, but may not revert soon
Key Metrics Compared 1 Yr Prior
| Metric | DHR | MEDP | IQV |
|---|---|---|---|
| P/OpInc* | 39.8x | 26.3x | 18.7x |
| LTM OpInc Growth | -6.5% | 32.7% | 10.1% |
| 3Y Avg OpInc Growth | -6.5% | 31.3% | 17.4% |
| LTM Revenue Growth | -0.1% | 11.8% | 2.8% |
| 3Y Avg Revenue Growth | -1.0% | 22.9% | 3.6% |
OpInc = Operating Income
Additional Metrics To Consider
| Metric | DHR | MEDP | IQV |
|---|---|---|---|
| P/S | 5.9x | 6.1x | 2.1x |
| Market Cap (Current) | $ 141.4 Bil | $ 13.1 Bil | $ 32.1 Bil |
| LTM Revenue | $ 23.82 Bil | $ 2.16 Bil | $ 15.50 Bil |
| LTM Opinc | $ 4.83 Bil | $ 456.32 Mil | $ 2.27 Bil |
| LTM Op Margin | 20.3% | 21.2% | 14.7% |
OpInc = Operating Income
Alternate buying based on valuation, while attractive, needs to be evaluated carefully from multiple angles. Such multi-factor analysis is exactly how we construct Trefis portfolio strategies. If you want upside with a smoother ride than an individual stock, consider the High Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception.